 GlaxoSmithKline PLC GSK, -0.18 announced Thursday an agreement to supply the Government of Canada with 20,000 doses of Sotrovimab, the COVID-19 monoclonal antibody therapy the company developed with Vir Biotechnology Inc. VIR, 0.20 . The agreement follows Canadas initial order of 10,000 doses of Sotrovimab announced in October, which included options for additional purchases. 